

剖析全球各大医药公司在中国的投资策略

China: The Key Pharmerging Market

– Deciphering Major Pharma Companies' China Strategy

By: Jim J. Zhang, Ph.D.

Publisher: JZMed, Inc.

April, 2010

Scope of the Report

It has been well recognized that the global pharmaceutical industry is currently experiencing drastic changes. All world major pharma companies are taking all necessary actions to make their organization more agile and adaptive and their operation more flexible and productive. These changes will ultimately lead to evolving of new operation models across the entire value chain of drug R&D, manufacturing and marketing.

While focusing on streamlining their internal operation, all world major pharma companies are also increasingly putting more of their focus on emerging markets as it has been widely recognized that most of the future market growth of the global pharmaceutical industry will be contributed by the emerging markets.

Among all emerging countries, China is currently standing out noticeably as it has displayed the fastest growth history in the past and, more importantly, still has huge future growth potential. Consequently, all world major pharma companies are currently placing more focus on China than any other countries in the same category and competing with each other in the Chinese market.

The report is focused on analyzing the strategies of entering China of these major pharma companies and their performance so far in the Chinese market. It is composed of four chapters. Each chapter focuses on addressing one type of critical issues.

Chapter One analyzed the current challenges faced by the world pharmaceutical industry and the strategies and actions currently taken by all major pharma companies. It pointed out that a series of new operation models are evolving in the industry.

Chapter Two analyzed the strategies currently taken by all world major pharma companies in the Chinese market and their activities in the country.

Chapter Three listed and analyzed in detail a whole spectrum of the activities of world top ten major pharma companies in the Chinese market. It vividly narrated a complete story of how each of these companies initially entered China, later expanded their presence and then become fully engaged in the Chinese market. It also revealed their marketing strategies, current performance and future growth potential in China.

Chapter Four analyzed the potential hurdles to be encountered by any foreign companies when they follow these major companies to enter the Chinese market. It also discussed all options they could have and their advantages and disadvantages.

The report provides by far the most comprehensive review, analysis and outlook about the world major pharmaceutical companies in the Chinese market.

About the Author

Jim J. Zhang, Ph. D.

Jim J. Zhang currently is president and managing director of JZMed, Inc., a leading market research company that specializes in the Chinese pharmaceutical, biotechnology and pharmaceutical outsourcing industries. Before founding the company, Jim worked for nine years with Albany Molecular Research, Inc. (AMRI), a US-based and currently one of the world largest CROs. During his tenure at AMRI Jim was responsible for managing and overseeing multiple drug R&D projects that involved the international cooperation of AMRI's multiple sites (USA, Singapore and Hungary). He played key roles in helping numerous pharma and biotech companies discover and develop a series of drug candidates that later entered preclinical and clinical development including advanced clinical trials. He was also the key contributor to the development of chemical production process for several developmental drugs. Prior to pursuing his Ph.D. program in the US, Jim worked for six years in a China-based CMO as process engineer and developed production process for a number of pharma products.

Jim's technical expertise spans from chemical process research and development to drug discovery and development for viral infection, cancer, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Currently he holds 18 patents. He is also the principal author of 12 peer-reviewed research articles.

Jim has authored a series of research reports about Chinese pharmaceutical outsourcing industry. He was also invited by a number of market research firms such as Business Insights to author/co-author industry reports.

Jim received his master's degree in Chemical Engineering from East China University of Science & Technology (Shanghai), and his Ph.D. degree in Synthetic Organic Chemistry from the University of Iowa. He also received additional trainings in Medicinal Chemistry through working at Research Triangle Institute (Research Triangle Park, North Carolina).

Report Description

It has been widely recognized that a series of changes is currently underway in the global pharmaceutical industry. All world major pharma companies are currently experiencing a number of common challenges, both internally and externally. These challenges have forced them to take all necessary actions including reducing the size of their internal R&D organization to increasingly use external resources, increasingly pursuing virtual R&D model by running the internal R&D in a way more like an R&D-focused biotech company and by focusing more on managing relationship with external partners, and closing more manufacturing facilities to outsource all general manufacturing tasks. All these actions aim to make their organization more agile and adaptive and their operation more flexible and productive.

These fundamental changes will ultimately lead to evolving of new operation models across the entire value chain of drug R&D, manufacturing and marketing. As a result, all world major pharma companies will become much slimmer and more reliant on outside. They will still conduct R&D in house but only to a minimum extent. They will still perform manufacturing tasks but only those critically important. They will still focus on marketing but the marketed products are not necessarily made by themselves.

One of the series of changes currently undertaken is the shift of marketing focus of the major pharma companies. They have now become more focused on the emerging markets. Whereas among all emerging economies, their focus is more on China than any others as they are all attracted by the fastest growth trend of the Chinese pharmaceutical market. So far all world major pharma companies have had a variety of activities in the country including R&D, manufacturing, outsourcing and marketing.

The report **“China: The Key Pharmemerging Market – Deciphering Major Pharma Companies’ China Strategy”** analyzed, both in detail and in depth, the whole spectrum of the activities of world top ten major pharma companies in the Chinese market. It revealed their investment and marketing strategies and R&D focus in China. It also surveyed the sales revenues of these major pharma companies in the Chinese market including their past growth history, current market size and future growth potential.

The report provides by far the most comprehensive review, analysis and outlook about the world major pharmaceutical companies in the Chinese market. It provides a clear insight into their motivations and strategies in the country. It is a must-read book to all organizations and professionals in the industries of pharmaceutical, biotechnology, outsourcing service and financial investment that plan to enter the Chinese market or are interested in learning how the major companies got a firm foothold in China.

Key Findings of the Report

- ❑ The global pharmaceutical industry is currently experiencing dynamic changes. Facing a series of common challenges, both internally and externally, all world major pharma companies are taking all necessary actions including vigorously controlling operation cost, simplifying organizational structure and increasingly using external resources.
- ❑ All these efforts will lead to evolving of new operation models spanning the entire value chain of drug R&D, manufacturing and marketing. In the future, all major pharma companies will become much slimmer. To them, searching for right drug candidates and technologies to license or right partners to collaborate with will become high priority. Similarly, searching for right service providers for outsourcing and right material suppliers for their supply chain will also become important to them. They will thus do more search than research.
- ❑ All world major pharma companies are also shifting their marketing focus more on to the dynamically rising emerging markets. The current top five major pharma companies in the emerging markets are: Sanofi-Aventis, Pfizer, GlaxoSmithKline, Astra-Zeneca and Novartis. Combined together, their current sales revenue in the emerging markets reached more than \$31 B, accounted for about 15% of their combined total global revenue and increased about 19% compared with 2008. The emerging markets have clearly become the battle ground of drug product marketing for all pharma companies.
- ❑ Among all emerging countries, China has become the main focus of all world pharma companies as the country presents enormous attractions such as the fastest growth of its pharmaceutical market whose growth momentum is further strengthened by the recently implemented healthcare reform. All world major pharma companies have had a wide variety of activities in the country in the past decade.
- ❑ The current top ten major pharma companies that are most active in the Chinese market are: Pfizer, Sanofi-Aventis, Bayer Schering, GlaxoSmithKline, Astra-Zeneca, Novartis, Roche, Johnson & Johnson, Merck and Eli Lilly. Combined together, they have so far invested more than \$3 B in China. Another \$2.2 B investment plan has been announced recently.
- ❑ In 2009 these top ten major pharma companies made the combined sales revenue of \$7.2 B in the Chinese market, accounting for about 18% of the current market value of Western-style medicines in the Chinese drug market. Compared to 2008, their combined sales revenue increased about 29%.
- ❑ The extraordinary growth of these major pharma companies in the Chinese market has made all of them determined to more dramatically increase their investment and

strengthen their presence in the country, which will only result in the faster growth of their China sales revenue in the near future. At present a common feature of their activity in China is that they have become fully engaged in the country.

Key Features of the Report

- ❑ By analyzing the current challenges faced by the global pharmaceutical industry, the report is focused on analyzing the strategies and actions currently taken by all world major pharma companies. It is the first time ever that the report pointed out the new development direction of the global pharmaceutical industry in the near future and the new operation models to be evolving.
- ❑ The report also analyzed the strategies currently taken by all world major pharmaceutical companies to enter and get a strong foothold in the emerging markets and their current activities and performance in these countries.
- ❑ With detailed summarization and analysis of all activities of world top ten major pharmaceutical companies in the Chinese market in the past decade, the report vividly narrated a complete story of how each of these companies initially entered China, later expanded their presence and then become fully engaged in the country. It is also the first time ever that the report revealed the strategies of all these world major pharmaceutical companies in the Chinese market. It provides real examples to all other companies that plan to follow them to enter the Chinese market.
- ❑ Moreover, the report analyzed both in detail and in depth what potential hurdles a foreign company could encounter when entering the Chinese market and options they could have. By comparing the advantages against the disadvantages of each of these options, the report provides strategic and detailed solutions to help these companies effectively overcome these hurdles.
- ❑ The report also surveyed the market performance of the world top ten major pharmaceutical companies in the Chinese market. It revealed the facts of how their China sales revenues climb up so fast, which company has had the most investment in China, which has had the most activities, which has had the best market performance so far and which will have the most potential of future growth.
- ❑ The report is a comprehensive reference book for any foreign companies that wish to enter the Chinese pharmaceutical market to look for existing examples, decide the best operation models and counsel the practical strategies.

Your Questions Are Answered

The Report provided detailed answers to a series of questions:

- Why are so many pharmaceutical companies from around the world going to China? What attract them? How do they weight these attractions?
- What strategies did these companies employ to enter the Chinese market? How did they gain a strong foothold in the country?
- What investment did they have in China? What are they doing currently?
- Where in China are the activities of these pharma companies most concentrated? Which places in China are most suitable for what type of pharma projects? How about the local investment environment?
- In the past which major pharma company has been most aggressively expanding its presence in China? Which one is most aggressive right now?
- What types of R&D are the major pharma companies currently conducting in China? Who in China have they collaborated with? What strategies did they employ to approach the local Chinese organizations? Which Chinese companies/research institutions have had the most collaborations with major pharma companies?
- Who are the current top ten foreign pharma companies in the Chinese market? How are they ranked?
- What drug products are they marketing in China? How are their market performances/shares in each sector of the Chinese market? What types of drug products have the best sales revenue and why?
- What hurdles will other pharma companies encounter if they follow these major companies to enter the Chinese market? What strategies should they employ to overcome them?

Table of Contents

Scope of the Report	2
About Author	3
Executive Summary	14
▪ A new era of global pharmaceutical industry: Evolving of new operation models driven by the difficulties encountered by all major pharma companies	
▪ Strategies of major pharma companies entering Chinese market	
▪ Top ten major pharma companies in China: Their activities, current market size and future growth prediction	
▪ Hurdles to entering Chinese market	
Chapter One: A New Era of Global Pharmaceutical Industry: Evolving of New Operation Models Driven by the Difficulties Encountered by All Major Pharma Companies	21
Summary	22
1.1 Introduction	24
1.2 Difficulties faced by all major pharmaceutical companies	25
1.2.1 Internal factors	25
1. Drying pipelines	25
2. Loss of sales revenues due to patent expiry	26
3. Escalating R&D cost due to high attrition rate and low productivity	29
1.2.2 External factors	29
1. Price containment by government	29
2. More scrutinizing on drug safety	30
3. Still high expectation for the pharma industry	30
1.3 Strategies previously taken by major pharma companies to cope with the situation	31
1.3.1 Passively trimming their own workforce	31
1.3.2 Tactically using external resources	33
1.3.3 Outcomes of the previous round of restructures – Problems still not solved	33
1.4 Impacts of the financial crisis on global pharmaceutical industry	34
1.5 Strategies currently pursued by major pharma companies	36
1.5.1 Cost reduction	37
1.5.2 Simplifying organization	38
1. R&D	38
a. Changing R&D models	38
(1) Internally, establishing smaller R&D organization	

and pursuing more virtual operation model -----	38
(2) Externally, pursuing more networked partnerships --	39
b. Strengthening technical capability -----	40
(1) Focusing more on genomics and proteomics research -----	40
(2) Reallocating more R&D budget to toxicology study and preclinical research -----	41
c. Reprioritizing R&D focus on late stage development and narrowing therapeutic focus -----	41
2. Manufacturing: Rapidly reducing capacity for small molecule drugs in particular those off-patented ones while still retaining and even enhancing capability and capacity for novel biologics ---	42
1.5.3 Increasing R&D outsourcing -----	45
1.5.4 Changing licensing model of drug candidates from small biotech companies -----	46
1.5.5 Becoming more adaptive to new technologies -----	47
1.5.6 Focusing more on emerging markets -----	47
1.5.7 Licensing generic drugs -----	50
1.5.8 Shifting product portfolio focus -----	51
1.6 Outlook of the future development of global pharmaceutical industry -----	51

**Chapter Two: Strategies of Major Pharma Companies Entering Chinese
Market ----- 55**

Summary -----	56
2.1 Introduction -----	58
2.2 China's attraction -----	59
2.2.1 World fastest growing pharmaceutical market -----	60
2.2.2 Key growth drivers of Chinese pharmaceutical market -----	64
1. On-going nationwide healthcare reform -----	64
2. Westernization of living style changing disease patterns -----	65
3. Rapid urbanization making more Chinese able to afford high-end medicines -----	65
2.3 Other advantages also attractive to major pharma companies -----	66
2.3.1 Rich natural products -----	66
2.3.2 A large, treatment-naïve patient pool -----	67
2.3.3 Abundant animal species -----	67
2.3.4 Large, well-trained workforce -----	68
2.3.5 Innovative drug R&D on the fast rise in China -----	71
2.4 An overview of the strategies of major pharma companies entering Chinese market -----	74
2.5 In-depth analysis of strategies and activities of major pharma companies in China -----	77
2.5.1 Major pharma companies' investment strategy and activities in China --	77
2.5.2 Major pharma companies' R&D strategy and activities in China -----	80
2.5.3 Major pharma companies' manufacturing strategy and activities in	

China -----	85
2.5.4 Major pharma companies' marketing strategy and activities in China ---	89
2.5.5 Major pharma companies' drug candidate licensing activities in China -	93
2.5.6 Collaborations of major pharma companies with local Chinese organizations -----	94
2.5.7 Major pharma companies' outsourcing strategies and the latest activities in China -----	97
1. R&D outsourcing -----	97
2. Manufacturing outsourcing and API sourcing -----	99
2.5.8 Summary -----	102

Chapter Three: Top Ten Major Pharma Companies in China: Their Activities, Current Market Size and Future Growth Prediction ----- 106

Summary -----	107
3.1 Introduction -----	109
3.2 Pfizer in China -----	110
3.2.1 Growth history, current state and future market growth prediction ---	110
1. R&D -----	110
2. Research collaboration and outsourcing -----	111
3. Manufacturing -----	111
4. Sales -----	113
3.2.2 Wyeth in China -----	114
3.2.3 Pfizer's activities in other emerging markets -----	115
3.3 Sanofi-Aventis in China -----	117
3.3.1 Growth history, current state and future market growth prediction ---	117
1. R&D -----	117
2. Research collaboration and outsourcing -----	118
3. Manufacturing -----	118
4. Sales -----	121
3.3.2 Sanofi-Aventis' activities in other emerging markets -----	122
3.4 GlaxoSmithKline in China -----	123
3.4.1 Growth history, current state and future market growth prediction ---	123
1. R&D -----	123
2. Research collaboration and outsourcing -----	123
3. Manufacturing -----	124
4. Sales -----	125
3.4.2 GSK's activities in other emerging markets -----	127
3.5 Roche in China -----	128
3.5.1 Growth history, current state and future market growth prediction ---	128
1. R&D -----	128
2. Research collaboration and outsourcing -----	129
3. Manufacturing -----	129
4. Sales -----	131
3.5.2 Roche's activities in other emerging countries -----	132
3.6 Novartis in China -----	133

3.6.1	Growth history, current state and future market growth prediction -----	133
1.	R&D -----	133
2.	Research collaboration and outsourcing -----	134
3.	Manufacturing -----	134
4.	Sales -----	136
3.6.2	Novartis' activities in other emerging countries -----	138
3.7	Astra-Zeneca in China -----	140
3.7.1	Growth history, current state and future growth prediction -----	140
1.	R&D -----	140
2.	Research collaboration and outsourcing -----	140
3.	Manufacturing -----	141
4.	Sales -----	143
3.7.2	Astra-Zeneca's activities in other emerging markets -----	144
3.8	Johnson & Johnson in China -----	146
3.8.1	Growth history, current state and future market growth prediction -----	146
1.	R&D -----	146
2.	Research collaboration and outsourcing -----	146
3.	Manufacturing -----	147
4.	Sales -----	148
3.8.2	J&J's activities in other emerging markets -----	149
3.9	Eli Lilly in China -----	150
3.9.1	Growth history, current state and future market growth prediction -----	150
1.	R&D -----	150
2.	Research collaboration and outsourcing -----	151
3.	Manufacturing -----	152
4.	Sales -----	153
3.9.2	Eli Lilly's activities in other emerging countries -----	154
3.10	Bayer in China -----	157
3.10.1	Growth history, current state and future market growth prediction -----	157
1.	R&D -----	157
2.	Research collaboration and outsourcing -----	158
3.	Manufacturing -----	158
4.	Sales -----	159
3.10.2	Bayer's activities in other emerging countries -----	161
3.11	Merck (MSD) in China -----	163
3.11.1	Growth history, current state and future growth prediction -----	163
1.	R&D -----	163
2.	Research collaboration and outsourcing -----	163
3.	Manufacturing -----	164
4.	Sales -----	165
3.11.2	Merck's activities in other emerging countries -----	166
Chapter Four: Hurdles to Entering Chinese Market -----		168
Summary -----		169
4.1	Introduction -----	171

4.2 Hurdles of sourcing APIs or contract manufacturing in China -----	172
4.3 Hurdle of outsourcing drug R&D to China -----	175
4.3.1 Imperfect IP protection environment -----	176
4.3.2 Still-need-improved service capability -----	176
4.3.3 Limited skills in innovative drug R&D -----	177
4.3.4 Regulation in clinical trial and drug approval -----	178
4.4 Possibility and hurdles of licensing drug candidates from Chinese biotech companies -----	178
4.5 Hurdles of marketing drug products in China and how to overcome them -----	179
4.5.1 Challenges -----	180
4.5.2 How to overcome them -----	181
4.6 Analysis of the best strategies to enter the Chinese market -----	182
4.6.1 Establishing a wholly owned facility (either manufacturing or R&D) --	182
1. Advantages -----	182
2. Disadvantages -----	183
4.6.2 Forming a joint venture (JV) -----	183
1. Advantages -----	183
2. Disadvantages -----	184
3. Strategies to safeguard IP and ensure product quality -----	184
4.6.3 Establishing a partnership -----	184
1. Advantages -----	184
2. Disadvantages -----	185
4.6.4 Outsourcing -----	185
1. Advantages -----	186
2. Keys to gain these advantages -----	186
3. Disadvantages -----	187
4.7 Strategic differences between managing a partnership and a straight outsourcing project in China -----	187
4.7.1 Partnership -----	188
1. Activities -----	188
2. Purposes of a partnership -----	189
3. Characteristics of a partnership -----	189
4.7.2 Outsourcing -----	189
1. Activities involved in outsourcing -----	189
2. Purposes of outsourcing -----	190
3. Characteristics of outsourcing -----	190
4.7.3 Advantages and disadvantages of managing a partnership and an outsourcing relationship in China -----	191
4.8 Advantages and disadvantages of building own facilities versus contracting out in China -----	192
4.9 How to overcome the hurdles of cultural difference -----	193
4.9.1 Main differences in culture and business conduct between the West and the East -----	194
1. Long-term business development goals versus short term business development goals -----	194
2. Assumed responsibility versus required responsibility -----	195

3. Consistency versus randomness -----	195
4. Business relationship versus personal relationship -----	196
4.9.2 Summary of the Characteristics of Chinese culture in business conduct -----	197
4.10 Strategies to effectively collaborate with Chinese companies -----	198
4.10.1 Select a Chinese partner/vendor carefully -----	198
4.10.2 Pay attention to relationship -----	198
4.10.3 Strategies to avoid conflicts and loss of your IPs -----	199
4.10.4 Strategies to resolve any issues/disputes in conducting business collaboration with a Chinese company -----	200
1. Quality issue -----	200
2. IP breach -----	201

Appendix -----	202
-----------------------	------------

Appendix I. List of Chinese companies and research institutions that have collaborated with major pharma companies -----	203
---	------------

Appendix II. Research Methodology -----	207
--	------------

Appendix III. About JZMed, Inc. -----	208
--	------------

List of Tables

Table 1. Blockbuster drugs going to lose patent protection before 2013 -----	27
Table 2. Number of companies having announced restructure during the financial crisis -----	35
Table 3. Current top five major pharma companies in emerging markets (their current sales revenue made from emerging markets and its proportion in their total global sales revenue) -----	49
Table 4. Comparisons between the old operation models and the new ones currently pursued by world major pharma companies -----	54
Table 5. Development history, current market size and future growth forecast of Western-style medicines in Chinese pharmaceutical market -----	61
Table 6. Top major pharma companies' investment in China -----	79
Table 7. Major pharma companies having investment branch in China -----	80
Table 8. Major pharma companies having (or planning to have) Asia-Pacific operation (or R&D) headquarters in China -----	80
Table 9. Major pharma companies having announced investment plans for building R&D centers in China -----	81
Table 10. China R&D centers of major pharma companies: Current size and research focuses -----	83
Table 11. Latest investment activities of major pharma companies in expanding their China manufacturing facilities or building new ones in the country ---	87
Table 12. Planned investment of major pharma companies to build more manufacturing facilities in China -----	89

Table 13. Major pharma companies ranked by their current (2009) China sales revenue -----	90
Table 14. Latest examples of major pharma companies collaborating with local Chinese companies on drug R&D -----	95
Table 15. Examples of major pharma companies training local Chinese hospital personnel -----	95
Table 16. Examples of major pharma companies collaborating with Chinese government agencies -----	96
Table 17. Latest examples of outsourcing and research collaborations between major pharma companies and Chinese companies/research institutions ----	98
Table 18. Summary of major pharma companies' China strategies and activities ----	102
Table 19. Predicted growth of top ten major pharma companies in Chinese market by 2012 -----	104
Table 20. Summary of top ten major pharma companies' complete presence in China -----	108
Table 21. List of Pfizer's current facilities in China -----	113
Table 22. Growth history and future growth prediction of Pfizer's sales revenue in Chinese market -----	115
Table 23. List of Sanofi-Aventis' current facilities in China -----	120
Table 24. Growth history and future growth prediction of Sanofi-Aventis' sales revenue in Chinese market -----	121
Table 25. List of GSK's current facilities in China -----	125
Table 26. Growth history and future growth prediction of GSK's sales revenue in Chinese market -----	126
Table 27. GSK's current sales performance in emerging markets and its future growth prediction -----	127
Table 28. List of Roche's current facilities in China -----	130
Table 29. Growth history and future growth prediction of Roche's sales revenue in Chinese market -----	131
Table 30. List of Novartis' current facilities in China -----	136
Table 31. Growth history, current market size and future growth prediction of Novartis in Chinese market -----	138
Table 32. List of Astra-Zeneca's current facilities in China -----	142
Table 33. Growth history, current market size and future growth prediction of Astra-Zeneca's sales revenue in Chinese market -----	143
Table 34. List of Johnson & Johnson's current facilities in China -----	148
Table 35. Growth history, current market size and future growth prediction of J&J's sales revenue in Chinese market -----	149
Table 36. List of Eli Lilly's current facilities in China -----	153
Table 37. Current market size, growth history and future growth forecast of Eli Lilly's China sales revenue -----	154
Table 38. List of Bayer's current facilities in China -----	159
Table 39. Current market size, growth history and future growth prediction of Bayer's sales revenue in Chinese market -----	161
Table 40. List of Merck's (MSD) current facilities in China -----	164
Table 41. Current market size, growth history and future growth prediction of	

Merck's (MSD) sales revenue in Chinese market -----	165
Table 42. Comparison of different approaches to product quality management between Chinese companies and Western companies -----	173
Table 43. Analysis of current issues in Chinese API supply chain and solutions to overcome them -----	174
Table 44. Comparison between partnership and pure outsourcing models -----	191
Table 45. Major characteristics of Chinese culture in business collaboration -----	197

List of Figures

Figure 1. Revenue loss during 2009 – 2013 in global pharmaceutical industry due to patent expiry -----	28
Figure 2. Graphic display of the number of companies experiencing restructure during the financial crisis -----	35
Figure 3. Growth trend of Pfizer's manufacturing outsourcing -----	43
Figure 4. Growth of top five major pharma companies in emerging markets -----	49
Figure 5. Evolving of new operation models within the global pharmaceutical industry -----	52
Figure 6. Major elements of China attracting foreign pharma companies -----	59
Figure 7. Fast growth trend of Chinese pharmaceutical market (Western-style medicines) -----	61
Figure 8. Milestones in the development process of Chinese pharmaceutical market -	64
Figure 9. Drug R&D platforms to be built in China -----	73
Figure 10. Four stages of major pharma companies' entrance into Chinese market ----	75
Figure 11. Summary of activities of major pharma companies in China -----	76
Figure 12. Wholly-owned R&D centers established in China by major pharma and biotech companies -----	82
Figure 13. Major pharma companies having manufacturing facilities in China -----	86
Figure 14. Current ranks of top ten major pharma companies in Chinese market based on their current (2009) China sales revenue -----	91
Figure 15. Average growth rate of top ten major pharma companies in last three years (2007 – 2009) in Chinese market -----	91
Figure 16. Predicted sales revenue of major pharma companies in Chinese market in 2012 -----	105
Figure 17. Chronic display of Pfizer's entrance into Chinese market -----	112
Figure 18. Growth history and future growth prediction of Pfizer's sales revenue in Chinese market -----	115
Figure 19. Chronic display of Sanofi-Aventis' entrance into Chinese market -----	119
Figure 20. Growth history and future growth prediction of Sanofi-Aventis' sales revenue in Chinese market -----	122
Figure 21. Chronic display of GSK's entrance into Chinese market -----	124
Figure 22. Growth history and future growth prediction of GSK's sales revenue in Chinese market -----	126
Figure 23. Chronic display of Roche's entrance into Chinese market -----	130
Figure 24. Growth history and future growth prediction of Roche's sales revenue in Chinese market -----	132

Figure 25. Chronic display of Novartis' entrance into Chinese market -----	135
Figure 26. Growth history and future growth prediction of Novartis' sales revenue in Chinese market -----	138
Figure 27. Chronic display of Astra-Zeneca's entrance into Chinese market -----	142
Figure 28. Growth history and future growth prediction of Astra-Zeneca's sales revenue in Chinese market -----	144
Figure 29. Chronic display of Johnson & Johnson's entrance into Chinese market --	147
Figure 30. Growth history and future growth prediction of Johnson & Johnson's sales revenue in Chinese market -----	149
Figure 31. Chronic display of Eli Lilly's entrance into Chinese market -----	152
Figure 32. Growth history and future growth prediction of Eli Lilly's sales revenue in Chinese market -----	154
Figure 33. Chronic display of Bayer's entrance into Chinese market -----	158
Figure 34. Growth history and future growth prediction of Bayer's sales revenue in Chinese market -----	161
Figure 35. Chronic display of Merck's (MSD) entrance into Chinese market -----	164
Figure 36. Growth history and future growth prediction of Merck's (MSD) sales revenue in Chinese market -----	166

List of Case Studies

Case Study 1. Escalating cost of drug R&D -----	24
Case Study 2. Gradually decreasing drug R&D productivity industry-wide in past decade -----	24
Case Study 3. Low productivity in major pharma companies in past two years -----	26
Case Study 4. A typical example of huge impact of patent expiration on a major pharma company's revenue -----	28
Case Study 5. Example of government forcing drug companies to reduce or cap the price of innovative drugs -----	29
Case Study 6. Slower revenue growth of entire pharmaceutical industry in past decade and next five years -----	31
Case Study 7. Examples of latest restructure by major pharma companies -----	32
Case Study 8. Biotech companies survived the first hit of financial crisis restructuring again -----	34
Case Study 9. Examples of reduction of R&D budget by major pharma companies --	37
Case Study 10. Major pharma companies are shrinking the size of their R&D organization and pursuing more virtual operation model -----	39
Case Study 11. Examples of major pharma companies increasingly utilizing external resources -----	39
Case Study 12. Pfizer increasing outsourcing proportion of its manufacturing business -----	43
Case Study 13. Global pharmaceutical outsourcing: An outlook of its future development -----	45
Case Study 14. Example of major pharma/biopharma companies successfully reducing their R&D budget by outsourcing to low cost regions -----	46
Case Study 15. Market share and performance of major pharma companies in	

emerging markets -----	47
Case Study 16. Major pharma companies licensing sales rights to generic drugs -----	50
Case Study 17. Western-made medicines dominating Chinese pharmaceutical market -----	61
Case Study 18. Future growth potential of Chinese pharmaceutical markets in some key therapeutic areas -----	62
Case Study 19. Fast growth of middle class Chinese population -----	63
Case Study 20. Example of the interest of major pharma companies in natural products derived from medicinal herbs of traditional Chinese medicines (TCMs) -----	66
Case Study 21. A unique class of workforce in China: Chinese returnees and its current state -----	68
Case Study 22. China's industry R&D capability on the fast rise -----	69
Case Study 23. The vast pool of skilled workforce in China is an alternative resource to major pharma companies to increase productivity -----	70
Case Study 24. Chinese government at various levels supporting the innovative drug R&D and development of biotech industry in the country -----	71
Case Study 25. How a major pharma typically got a foothold in China -----	74
Case Study 26. Major pharma companies starting paying attention to innovative drugs discovered by Chinese companies -----	84
Case Study 27. Major pharma companies conducting full scale drug R&D in China -	94
Case Study 28. Astra-Zeneca contracting out IP sensitive R&D projects to Chinese CROs -----	97
Case Study 29. Example of risk-sharing outsourcing model between a Chinese company and a major pharma company -----	98
Case Study 30. Examples of major pharma companies sourcing pharma intermediates and APIs in China -----	99
Case Study 31. Astra-Zeneca will stop manufacturing and outsource all APIs -----	100
Case Study 32. Genzyme outsourcing manufacturing of one of its gene therapy drugs to China -----	102

About JZMed, Inc.

JZMed, Inc. (www.jzmedi.com) is a leading market research and consulting company that specializes in the Chinese pharmaceutical, biotechnology and pharmaceutical outsourcing industries. The company's primary focus is to provide intelligence and market research services to global pharmaceutical and biotech companies to help them tap the resources in the Chinese pharmaceutical industry and explore the opportunities in the Chinese pharmaceutical market. Meanwhile, it also provides assistance to these companies to facilitate their entrance into the Chinese pharmaceutical market or collaborations with Chinese companies. The company has provided this type of services to a variety of companies worldwide including the world major pharma companies and investment firms/banks. It also has a network of preferred pharma and biotech companies in China.

To Order

Information about the Report:

Publisher: JZMed, Inc.

Total number of pages: 208

Date published: April, 2010

Readers interested in the report can contact JZMed, Inc. at order@jzmedi.com.

Report ordering can also be processed through PayPal, secured online payment, directly at the website of JZMed, Inc. (www.jzmedi.com). All major credit cards are accepted.